Tectonic Therapeutic Q3 net loss widens 12% year over year to $21.35 million

Bitget2026/11/05 21:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tectonic Therapeutic’s third-quarter 2026 net loss widened 12% year over year to $21.35 million.
Operating expenses rose 7% year over year to $23.46 million.
Cash and cash equivalents totaled $234.7 million at September 30, 2026, with runway expected into Q1 2029.
Topline results from the TX45 APEX Phase 2 trial in PH-HFpEF are expected by the end of January 2027.
TX2100’s TERRA Phase 1b trial is expected to start by year-end 2026, followed by the TIDAL Phase 2 trial in early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051601PRIMZONEFULLFEED9871600) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tectonic Therapeutic Q3 net loss widens 12% year over year to $21.35 million

You may also like

Crypto prices